Lisa Carey, MD, and Kathy Albain, MD, on Results of the SWOG-8814 Trial

Lisa A. Carey, MD, of the University of North Carolina, and Kathy S. Albain, MD, of Loyola University Medical Center, discuss molecular predictors of outcome on adjuvant CAF plus tamoxifen, vs tamoxifen in postmenopausal patients with estrogen receptor–positive, node-positive breast cancer (Abstract S3-02).

Related Videos

Breast Cancer

Andrew Seidman, MD, and Ruth M. O’Regan, MD

Andrew Seidman, MD, and Ruth O'Regan, MD: Update on Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Ruth M. O’Regan, MD, of the University of Wisconsin, review practice-changing research in 2015 t...

Breast Cancer

Gunter von Minckwitz, MD

Gunter von Minckwitz, MD: Early Survival Analysis of GeparSixto

Gunter von Minckwitz, MD, of the German Breast Group, discusses data from this phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative a...

Breast Cancer

Andrew Seidman, MD, and Norman Wolmark, MD

Andrew Seidman, MD, and Norman Wolmark, MD, on NSABP Clinical Trials and Management of Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Norman Wolmark, MD, of Allegheny General Hospital, discuss the landmark trials of NSABP that hav...

Breast Cancer

Sarat Chandarlapaty, MD, PhD

Sarat Chandarlapaty, MD, PhD, on BOLERO-2 Clinical Trial Results

Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who ha...

Breast Cancer

Lisa A. Carey, MD, and Jay Harris, MD

Lisa Carey, MD, and Jay Harris, MD, on Critical Decision Making in Radiation Therapy for Breast Cancer

Lisa A. Carey, MD, of the University of North Carolina, and Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discuss Dr. Harris' p...